Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy

Ítems similars

• Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells
  per: Foy, Susan P., et al.
  Publicat: (2016)
• Poxvirus immunotherapies in combination with immune checkpoint inhibitors synergize to eliminate tumors in a mouse tumor model
  per: Foy, Susan P, et al.
  Publicat: (2013)
• Poxvirus-based active immunotherapy synergizes with immune checkpoint inhibitors to cause tumor regression and extend survival in preclinical models of cancer
  per: Foy, Susan P, et al.
  Publicat: (2014)
• Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice
  per: Foy, Susan P., et al.
  Publicat: (2016)
• Development of PROSTVAC immunotherapy in prostate cancer
  per: Singh, Parminder, et al.
  Publicat: (2015)